Sep 8, 2026 08:15AM
Sep 8, 2026 08:15AM
Aug 27, 2026 09:01AM
Aug 27, 2026 09:01AM
Aug 24, 2026 09:05AM
Aug 24, 2026 09:05AM
Jun 18, 2026 08:32AM FDA grants orphan drug status to GRI Bio's GRI-0621 for lung disease
Jun 18, 2026 08:31AM
May 18, 2026 09:15AM
May 14, 2026 08:35AM
May 14, 2026 08:35AM
Feb 5, 2026 09:15AM
Feb 4, 2026 08:47AM
Feb 4, 2026 08:45AM GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Jan 28, 2026 08:45AM
Jan 28, 2026 08:45AM
Jan 26, 2026 08:30AM
Jan 21, 2026 04:01PM
Jan 21, 2026 04:01PM
Jan 8, 2026 08:00AM
Jan 8, 2026 08:00AM GRI Bio Announces Additional Positive Data from Phase 2a Study in Idiopathic Pulmonary Fibrosis, Strengthening Clinical Proof-of-Concept for GRI-0621
Dec 12, 2025 04:05PM
Dec 12, 2025 04:05PM
Dec 11, 2025 09:15AM
Dec 11, 2025 09:15AM
Dec 10, 2025 04:05PM
Dec 10, 2025 04:05PM
Sep 11, 2025 08:45AM GRI Bio reports no lung function decline in IPF trial interim data
Sep 11, 2025 08:45AM
Jul 31, 2025 09:00AM
Jul 31, 2025 09:00AM
Jul 1, 2025 08:45AM
Jun 26, 2025 08:08AM
Jun 26, 2025 08:00AM
May 22, 2025 08:03AM GRI Bio, Inc (GRI) Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Re
May 22, 2025 08:00AM
May 15, 2025 08:35AM
May 15, 2025 08:35AM
May 8, 2025 08:48AM
May 8, 2025 08:45AM
May 7, 2025 09:15AM
Apr 16, 2025 08:35AM GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference
Apr 2, 2025 04:05PM
Apr 1, 2025 11:15AM
Apr 1, 2025 11:15AM
Apr 1, 2025 09:00AM
Apr 1, 2025 09:00AM
Mar 31, 2025 08:03AM
Mar 31, 2025 08:00AM GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan
Mar 18, 2025 09:05AM

1,187,483 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All